Trends in the clinical characteristics of HIV-infected patients initiating antiretroviral therapy in Kenya, Uganda and Tanzania between 2002 and 2009

Journal of the International AIDS Society

Volumn 14, Issue 1, 2011, Pages

  Geng, Elvin H ^a   Hunt, Peter W ^a   Diero, Lameck O ^f   Kimaiyo, Sylvester ^f   Somi, Geofrey R ^d   Okong, Pius ^h   Bangsberg, David R ^c,g   Bwana, Mwebesa B ^c   Cohen, Craig R ^a   Otieno, Juliana A ^j   Wabwire, Deo ⁱ   Elul, Batya ^k   Nash, Denis ^k   Easterbrook, Philippa J ^e   Braitstein, Paula ^b   Musick, Beverly S ^b   Martin, Jeffrey N ^a   Yiannoutsos, Constantin T ^b   Wools Kaloustian, Kara ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b INDIANA UNIVERSITY   (United States)

^c MBARARA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Uganda)

^d National AIDS Control Program   (Tanzania)

^e Infectious Diseases Institute   (Uganda)

^f MOI UNIVERSITY   (Kenya)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h St Francis Hospital Uganda   (Uganda)

ⁱ MAKERERE UNIVERSITY   (Uganda)

^j Kisumu MTCT Plus Initiative ^*  (Kenya)

^k International Center for AIDS Care and Treatment Programs   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

NEVIRAPINE; STAVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; DEMOGRAPHY; FEMALE; GENDER; HEALTH CARE ACCESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KENYA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; POISSON DISTRIBUTION; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TANZANIA; TUBERCULOSIS; UGANDA; WORLD HEALTH ORGANIZATION; CROSS-SECTIONAL STUDY; DRUG UTILIZATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; IMMUNOLOGICAL TOLERANCE; METHODOLOGY; MIDDLE AGED; PATHOLOGY; SEX DIFFERENCE; STATISTICS; VIROLOGY;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; DRUG UTILIZATION; FEMALE; HIV INFECTIONS; HUMANS; IMMUNE TOLERANCE; KENYA; MALE; MIDDLE AGED; NEVIRAPINE; SEX FACTORS; STAVUDINE; TANZANIA; UGANDA;

EID: 80053367524     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.1186/1758-2652-14-46     Document Type: Article

References (25)

1. Office of the United States Global AIDS Coordinator. The Power of Partnerships: The President's Emergency Plan for AIDS Relief Fifth Annual Report to Congress 2009. 2009 http://www.pepfar.gov/documents/organization/81019.pdf Accessed July 21, 2010
2. AIDS epidemic update December 2009. http://data.unaids.org/pub/Report/ 2009/JC1700-Epi-Update-2009-en.pdf
3. AIDS epidemic update December 2010. http://www.who.int/hiv/pub/ 2010progressreport/report/en/index.html
4. The economic impact of AIDS treatment: labor supply in western Kenya. Thirumurthy H, Goldstein M, Graff Zivin J, Journal of Human Resources 2008 43 511 552
5. A national survey of teachers on antiretroviral therapy in Malawi: access, retention in therapy and survival. Makombe SD, Jahn A, Tweya H, Chuka S, Yu JK, Hochgesang M, Aberle-Grasse J, Thambo L, Schouten EJ, Kamoto K, Harries AD, PLoS One 2007 2 620 10.1371/journal.pone.0000620 17637836 (Pubitemid 351314467)
6. Mortality in HIV-infected Ugandan adults receiving antiretroviral treatment and survival of their HIV-uninfected children: a prospective cohort study. Mermin J, Were W, Ekwaru JP, Moore D, Downing R, Behumbiize P, Lule JR, Coutinho A, Tappero J, Bunnell R, Lancet 2008 371 752 759 10.1016/S0140-6736(08) 60345-1 18313504 (Pubitemid 351297773)
7. AIDS treatment and intrahousehold resource allocation: children's nutrition and schooling. Graff Zivin J, Goldstein M, Thirumurthy H, Journal of Public Economics 2009 93 1008 1015 10.1016/j.jpubeco.2009.03.003
8. Antiretroviral therapy in Africa. Stevens W, Kaye S, Corrah T, Bmj 2004 328 280 282 10.1136/bmj.328.7434.280 14751902 (Pubitemid 38168143)
9. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R, AIDS 2008 22 1897 1908 10.1097/QAD.0b013e32830007cd 18784453
10. Cryptococcocal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programme. Lawn SD, Bekker LG, Myer L, Orrell C, Wood R, Aids 2005 19 2050 2052 10.1097/01.aids.0000191232.16111.f9 16260920 (Pubitemid 41669038)
11. Improving enrollment and retention of youth into HIV services: lessons learned from Kisumu, Kenya. Otieno V, Marima R, Odhiambo J, Penner J, Ooko H, Agot K, Bukusi E, Cohen C, 17th International AIDS Conference; August 3-8, 2008; Mexico City 2008 19062402
12. Mortality and loss-to-follow-up during the pre-treatment period in an antiretroviral therapy programme under normal health service conditions in Uganda. Amuron B, Namara G, Birungi J, Nabiryo C, Levin J, Grosskurth H, Coutinho A, Jaffar S, BMC Public Health 2009 9 290 10.1186/1471-2458-9-290 19671185
13. Transportation Costs Impede Sustained Adherence and Access to HAART in a Clinic Population in Southwestern Uganda: A Qualitative Study. Tuller DM, Bangsberg DR, Senkungu J, Ware NC, Emenyonu N, Weiser SD, AIDS Behav 2009
14. World Health Organization HIV/AIDS Programme. Antiretroviral Therapy for Adults and Adolescents: Recommendations for a Public Health Approach 2010 Revision. 2010 http://www.who.int/hiv/pub/guidelines/en/ Accessed Sept. 20, 2010
15. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Gilks CF, Crowley S, Ekpini R, Gove S, Perriens J, Souteyrand Y, Sutherland D, Vitoria M, Guerma T, De Cock K, Lancet 2006 368 505 510 10.1016/S0140-6736(06)69158-7 16890837 (Pubitemid 44142772)
16. Bringing context back into epidemiology: variables and fallacies in multilevel analysis. Diez-Roux AV, Am J Public Health 1998 88 216 222 10.2105/AJPH.88.2.216 9491010 (Pubitemid 28134079)
17. Multilevel analysis in public health research. Diez-Roux AV, Annu Rev Public Health 2000 21 171 192 10.1146/annurev.publhealth.21.1.171 10884951 (Pubitemid 30480321)
18. A modified poisson regression approach to prospective studies with binary data. Zou G, Am J Epidemiol 2004 159 702 706 10.1093/aje/kwh090 15033648 (Pubitemid 38405384)
19. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. Oyugi JH, Byakika-Tusiime J, Ragland K, Laeyendecker O, Mugerwa R, Kityo C, Mugyenyi P, Quinn TC, Bangsberg DR, Aids 2007 21 965 971 10.1097/QAD. 0b013e32802e6bfa 17457090 (Pubitemid 46684328)
20. Late-disease stage at presentation to an HIV clinic in the era of free antiretroviral therapy in Sub-Saharan Africa. Kigozi IM, Dobkin LM, Martin JN, Geng EH, Muyindike W, Emenyonu NI, Bangsberg DR, Hahn JA, J Acquir Immune Defic Syndr 2009 52 280 289 10.1097/QAI.0b013e3181ab6eab 19521248
21. Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002-2007. Cornell M, Grimsruda A, Fairall F, Fox MP, van Cutsem G, Giddy J, Wood R, Prozesky H, Mohapi L, Graber C, et al. AIDS 2010 24 2263 2270 10.1097/QAD.0b013e32833d45c5 20683318
22. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, Costagliola D, D'Arminio Monforte A, de Wolf F, Reiss P, et al. Lancet 2002 360 119 129 10.1016/S0140-6736(02)09411-4 12126821 (Pubitemid 34786200)
23. Tuberculosis treatment and risk of stavudine substitution in first-line antiretroviral therapy. Westreich DJ, Sanne I, Maskew M, Malope-Kgokong B, Conradie F, Majuba P, Funk MJ, Kaufman JS, Van Rie A, Macphail P, Clin Infect Dis 2009 48 1617 1623 10.1086/598977 19385733
24. Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis. Cohen K, van Cutsem G, Boulle A, McIlleron H, Goemaere E, Smith PJ, Maartens G, J Antimicrob Chemother 2008 61 389 393 18096560
25. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study. Manosuthi W, Sungkanuparph S, Tantanathip P, Lueangniyomkul A, Mankatitham W, Prasithsirskul W, Burapatarawong S, Thongyen S, Likanonsakul S, Thawornwa U, et al. Clin Infect Dis 2009 48 1752 1759 10.1086/599114 19438397